- Business Wire•6 days ago
Alkermes to Present Data on Two-Month Dosing Option Of ARISTADA® at 16th International Congress on Schizophrenia Research
Alkermes plc today announced that data for the two-month dosing option of ARISTADA® extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress on Schizophrenia Research in San Diego, March 24-28, 2017.
- Zacks•8 days ago
Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.
- Business Wire•10 days ago
Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
Alkermes plc today announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate prodrug candidate in development for the treatment of relapsing forms of multiple sclerosis .
ALKS : Summary for Alkermes plc - Ordinary Shares - Yahoo Finance
Alkermes plc (ALKS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||45.03 x 1000|
|Day's Range||58.13 - 59.80|
|52 Week Range||30.03 - 62.50|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-42.67|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|